Rajesh Malik Net Worth

The estimated Net Worth of Rajesh Malik is at least $1.15 Million dollars as of 28 January 2019. Rajesh Malik owns over 7,000 units of G1 Therapeutics stock worth over $460,474 and over the last 2 years he sold GTHX stock worth over $0. In addition, he makes $688,715 as Chief Medical Officer and Senior Vice President – Research and Development at G1 Therapeutics.

Rajesh Malik GTHX stock SEC Form 4 insider trading

Rajesh has made over 15 trades of the G1 Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 7,000 units of GTHX stock worth $2,730 on 28 January 2019.

The largest trade he’s ever made was exercising 10,076 units of G1 Therapeutics stock on 15 October 2018 worth over $18,238. On average, Rajesh trades about 3,942 units every 22 days since 2018. As of 28 January 2019 he still owns at least 21,700 units of G1 Therapeutics stock.

You can see the complete history of Rajesh Malik stock trades at the bottom of the page.

Rajesh Malik biography

Dr. Rajesh K. Malik M.D. is the Chief Medical Officer, Senior Vice President – Research and Development of G1 Therapeutics Inc. Dr. Malik has served as our Chief Medical Officer since July 2014 and Chief Medical Officer and Senior Vice President of Research and Development since January 2018. Prior to becoming our Chief Medical Officer, Dr. Malik served as a consultant for business, clinical and regulatory matters from May 2013 through July 2014, including as a consultant to our Company from July 2013 to June 2014. Prior to joining us, Dr. Malik served as Chief Medical Officer of Agennix AG, a German biotechnology company, from January 2007 to September 2013, and as a member of the management board of Agennix AG from November 2009 to September 2013. Dr. Malik also served as Chief Medical Officer of Adherex Technologies, Inc., a biopharmaceutical company, from September 2004 to January 2007. Dr. Malik also served as an attending physician at the University of Virginia Medical Center and on the faculty of the University of Virginia School of Medicine. Dr. Malik earned his M.B. and Ch.B. from the University of Sheffield Medical School.

What is the salary of Rajesh Malik?

As the Chief Medical Officer and Senior Vice President – Research and Development of G1 Therapeutics, the total compensation of Rajesh Malik at G1 Therapeutics is $688,715. There are 6 executives at G1 Therapeutics getting paid more, with John Demaree having the highest compensation of $7,466,410.

How old is Rajesh Malik?

Rajesh Malik is 60, he’s been the Chief Medical Officer and Senior Vice President – Research and Development of G1 Therapeutics since 2018. There are 4 older and 9 younger executives at G1 Therapeutics. The oldest executive at G1 Therapeutics, Inc. is Fredric Eshelman, 70, who is the Independent Director.

Insider trading at G1 Therapeutics

Over the last 2 years, insiders at G1 Therapeutics have traded over $51,509,269 worth of G1 Therapeutics stock and bought 1,482,753 units worth $23,467,604 . The most active insider traders include Capital Management, Llcra C…, Fredric N Eshelman, and Glenn P Muir. On average, G1 Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $994,813. The most recent stock trade was executed by Jennifer K. Moses on 18 July 2019, trading 2,000 units of GTHX stock currently worth $7,440.

What does G1 Therapeutics do?

G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage biopharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

What does G1 Therapeutics’s logo look like?

Complete history of Rajesh Malik stock trades at G1 Therapeutics

G1 Therapeutics executives and stock owners

G1 Therapeutics executives and other stock owners filed with the SEC include:

• John Demaree, Chief Commercial Officer
• James Hanson, General Counsel
• Terry Murdock, Chief Operating Officer
• Mark Velleca, President, Chief Executive Officer, Director
• Garry Nicholson, Independent Chairman of the Board
• Barclay Phillips, Chief Financial Officer and Senior Vice President – Corporate Development
• Rajesh Malik, Chief Medical Officer, Senior Vice President – Research and Development
• Cynthia Schwalm, Independent Director
• Willie Deese, Independent Director
• Seth Rudnick, Independent Director
• Glenn Muir, Independent Director
• Fredric Eshelman, Independent Director
• Andrew Witty, Independent Director
• Jeff Macdonald, Head of Investor Relations/Public Relations
• Jennifer Moses, Vice President – Finance and Accounting
• Jay Strum, Chief Scientific Officer
• Clay Hatteras Venture Advis…,
• Capital Management, Llcra C…,
• Christy L Shaffer, Director
• Ventures, Inc. Med Immune, 10% owner
• Ventures, Llc Eshelman, 10% owner
• Clay Hatteras Venture Advis…,
• Mark Avagliano, Chief Business Officer